● Recruiting

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Condition: Acute Myeloid Leukaemia (AML) · Sponsor: Moleculin Biotech, Inc.

PhasePhase 2/Phase 3

Planned participants312

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.

This description comes directly from the study's public registry record.

Talk to the study team

Paul Waymack, MD, Sc.D · +1 202-760-1378 · pwaymack@moleculin.com

Erikson Wasyl, MS · 860-395-9275 · ewasyl@moleculin.com

Always discuss trial participation with your own doctor first.

Locations (25)

Bioresearch Partners	Miami, Florida, United States	Recruiting
Augusta University - Georgia Cancer Center	Augusta, Georgia, United States	Recruiting
University of Nebraska Medical Center	Omaha, Nebraska, United States	Recruiting
Atlantic Health	Morristown, New Jersey, United States	Recruiting
University Hospitals Cleveland Medical Center	Cleveland, Ohio, United States	Recruiting
University of Pennsylvania	Philadelphia, Pennsylvania, United States	Recruiting
GEORGIA: LLC ARENSIA Exploratory Medicine	Tbilisi, Georgia	Recruiting
Caucasus Medical Center	Tbilisi, Georgia	Recruiting
RCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia	Bologna, Italy	Recruiting
AOU Careggi	Florence, Italy	Recruiting
AUSL della Romagna - Santa Maria delle Croci - Ravenna	Ravenna, Italy	Recruiting
Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart	Roma, Italy	Recruiting

+ 13 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06788756